NNKTT120, an anti-iNKT cell monoclonal antibody, produces rapid and sustained iNKT cell depletion in adults with sickle cell disease
Authors:
Open Access
- 2 February 2017
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 12 (2) , e0171067
Abstract
Invariant NKT (iNKT) cells can be activated to stimulate a broad inflammatory response. In murine models of sickle cell disease (SCD), interruption of iNKT cell activity prevents tissue injury from vaso-occlusion. NKTT120 is an anti-iNKT cell monoclonal antibody that has the potential to rapidly and specifically deplete iNKT cells and, potentially, prevent vaso-occlusion. We conducted an open-label, multi-center, single-ascending-dose study of NKTT120 to determine its pharmacokinetics, pharmacodynamics and safety in steady-state patients with SCD. Doses were escalated in a 3+3 study design over a range from 0.001 mg/kg to 1.0 mg/kg. Twenty-one adults with SCD were administered NKTT120 as part of 7 dose cohorts. Plasma levels of NKTT120 predictably increased with higher doses. Median half-life of NKTT120 was 263 hours. All subjects in the higher dose cohorts (0.1 mg/kg, 0.3 mg/kg, and 1 mg/kg) demonstrated decreased iNKT cells below the lower limit of quantification within 6 hours after infusion, the earliest time point at which they were measured. In those subjects who received the two highest doses of NKTT120 (0.3, 1 mg/kg), iNKT cells were not detectable in the peripheral blood for a range of 2 to 5 months. There were no serious adverse events in the study deemed to be related to NKTT120. In adults with SCD, NKTT120 produced rapid, specific and sustained iNKT cell depletion without any infusional toxicity or attributed serious adverse events. The next step is a trial to determine NKTT120’s ability to decrease rate of vaso-occlusive pain episodes. Trial Registration: clinicaltrials.gov NCT01783691.Keywords
Funding Information
- NKT Therapeutics Inc.
This publication has 44 references indexed in Scilit:
- Invariant natural killer T cells recognize lipid self antigen induced by microbial danger signalsNature Immunology, 2011
- Invariant natural killer T cells recognize glycolipids from pathogenic Gram-positive bacteriaNature Immunology, 2011
- PLZF induces an intravascular surveillance program mediated by long-lived LFA-1–ICAM-1 interactionsJournal of Experimental Medicine, 2011
- Invariant natural killer T cells: bridging innate and adaptive immunityCell and tissue research, 2010
- A DIRECT ROLE FOR SECRETORY PHOSPHOLIPASE A2 AND LYSOPHOSPHATIDYLCHOLINE IN THE MEDIATION OF LPS-INDUCED GASTRIC INJURYShock, 2010
- The risks and benefits of long‐term use of hydroxyurea in sickle cell anemia: A 17.5 year follow‐upAmerican Journal of Hematology, 2010
- Modulation of human natural killer T cell ligands on TLR-mediated antigen-presenting cell activationProceedings of the National Academy of Sciences, 2007
- Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activationJournal of Experimental Medicine, 2006
- Understanding the function of CD1-restricted T cellsNature Immunology, 2003
- CD1d-dependent macrophage-mediated clearance of Pseudomonas aeruginosa from lungNature Medicine, 2002